Claims PTO
Tplunkett
8/24/04

1. A recombinant RNA molecule which can be translated at least partly in a target cell, comprising a noninfectious virus genome of Coxsackie virus group B, preferably serotype B3, and at least one foreign gene which causes a desired function in the target cell, for example within the framework of a gene therapy.

2. **(Amended)** The RNA molecule of Claim 1, **[characterized in that it]** which is replication-competent in the target cell.

3. **(Amended)** The RNA molecule of Claim 1 **[or 2], [characterized in that]** wherein in the virus genome parts of its coding sequence have been replaced by the at least one foreign gene.

4. **(Amended)** The RNA molecule of Claim **[3]** 2, **[characterized in that]** wherein in the virus genome the sequences of its capsid proteins VP1-VP4 have been replaced by the at least one foreign gene.

5. **(Amended)** The RNA molecule of Claim **[3 or 4]** 2, **[characterized in that]** wherein in the virus genome the sequences of its protease 2A and/or 3C have been **[replaced or]** modified such that there is no cytotoxicity for the target cell.

6. **(Amended)** The RNA molecule of **[any of claims 3 to 5]** Claim 2, **[characterized in that]** wherein in the virus genome the sequences of its helicase 2C have been replaced by the at least one foreign gene.

7. **(Amended)** The RNA molecule of **[any of claims 3 to 6]** Claim 2, **[characterized in that]** wherein in the virus genome the sequences of its protein 2B have been replaced by the at least one foreign gene.

claim 8 is cancelled

9. **(Amended)** A recombinant, infectious virion which is derived from Coxsackie Virus group B, preferably serotype B3, and whose genome comprises **[is]** the RNA molecule of **[any of Claims 1 to 7]** Claim 1.

10. **(Amended)** The virion of Claim 9, **[characterized in that it]** which corresponds in its structural proteins to a Coxsackie virus group B, preferably serotype B3.

Claim 11 is cancelled

12. **(Amended)** A vector plasmid having at least one DNA sequence which codes for the RNA molecule of **[any of Claims 1 to 7]** Claim 1 and having a promoter located in front of the DNA sequence.

13. **(Amended)** A helper construct for complementing the coding sequences replaced in the RNA molecule of **[any of Claims 1 to 7]** Claim 1.

14. **(Amended)** The helper construct of Claim 13, **[characterized in that it]** which is a helper plasmid which codes for at least one of the replaced sequences in a translatable manner.

15. **(Amended)** The helper construct of Claim 13, **[characterized in that it]** which is a viral vector which codes for at least one of the replaced sequences in a translatable manner.

16. **(Amended)** The helper construct of Claim 13, **[characterized in that it]** which is a helper cell which has been transfected stably with helper DNA coding for at least one of the replaced sequences.

Claims 17-20 are cancelled

21. **(Amended)** A kit, **[with]** comprising the vector plasmid of Claim **[13]** 12 and the helper construct of **[any of claims]** Claim 13**[to 16]**.

22. **(Amended)** A DNA molecule having at least one sequence section coding for the RNA molecule of **[any of claims 1 to 7]** Claim 1.

23. A kit with a DNA molecule of claim 22.

Claim 24 is cancelled.

25. **(Amended)** A therapeutic composition **[with]** comprising the RNA molecule of **[any of claims 1 to 7]** Claim 1.

26. A therapeutic composition with the vector plasmid of claim 12.

27. **(Amended)** A therapeutic composition with **[virions]** the virion of Claim 9 **[or claim 10]**.

28. **(Amended)** A DNA construct which codes for the RNA molecule of **[any of Claims 1 to 7]** Claim 1 and which persists and transcribes in a target cell but preferably does not replicate in the latter.

29. **(Amended)** A recombinant virus, preferably adeno- or retrovirus, which codes for the recombinant RNA molecule of **[any of Claims 1 to 7]** Claim 1 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.

Claims 31 and 32 are cancelled.